Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase three clinical trial of the combination of HLX78 (lasofoxifene) and abemaciclib to the combination of fulvestrant and abemaciclib in mainland China, excluding the Hong Kong, Macau, and Taiwan regions.
The combination is being tested for the treatment of pre- and post-menopausal women and men with locally advanced or metastatic breast cancer, a Tuesday bourse filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。